Trial reportJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2026
Phase 2 Study of Amivantamab Plus Lazertinib in Previously Treated Patients With EGFR-Mutant Lung Cancers With Brain and Leptomeningeal Metastases.
Trial report in Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04965090 (A Phase 2 Single-Arm Study of Amivantamab), which is not on this map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 2 Single-Arm Study of Amivantamab (JNJ-61186372) and Lazertinib in Metastatic EGFR-mutant Lung Cancer With Progressive or New CNS Metastases on Previous Treatment
Who cites it
8 citing papers in PubMed.
- Unlocking the central nervous system sanctuary inTranslational lung cancer research · 2026Article
- Review
- Risk Stratification and Strategies Towards Front-Line Therapy of EGFR-Mutant NSCLC: A Narrative Review.Cancers · 2026Review
- Review
- EGFR-TKI monotherapy versus combination therapy as first-line treatment for EGFR-mutant NSCLC with brain metastases: a real-world comparison analysis.BMC cancer · 2026Article
- Multimodality salvage treatment incorporating ivonescimab plus chemotherapy for EGFR-mutated NSCLC with leptomeningeal metastases after dose-escalated third-generation EGFR-TKI failure: a retrospective study.Frontiers in immunology · 2026Article
- Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC - mechanisms and evolving treatment approaches.Nature reviews. Clinical oncology · 2026Review
- Leptomeningeal metastatic disease responding to carboplatin, pemetrexed, and amivantamab after progression to osimertinib in EGFR exon 21 L858R-Mutated non-small cell lung cancer: Two case reports.Respiratory medicine case reports · 2026Article
Corrections and comments
- Commented on by
Authors and funding
25 authors.
Funding
Abstract
introductionDespite improved central nervous system (CNS) disease control with osimertinib, 20% of patients will develop CNS progression. Amivantamab and lazertinib have demonstrated activity in patients with EGFR-mutant lung cancer. This trial evaluated amivantamab and lazertinib in patients with new or progressive CNS metastases after prior therapy (NCT04965090).
methodsWe evaluated amivantamab and lazertinib in two cohorts: patients with (1) brain metastases (BrM) or (2) leptomeningeal disease (LMD) diagnosed by cytology in patients with lung cancers with sensitizing EGFR-activating mutations or exon 20 insertions. The primary end point was composite best overall response rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1 and Response Assessment in Neuro-Oncology brain metastases or Response Assessment in Neuro-Oncology leptomeningeal metastases. Secondary end points were toxicity, systemic ORR, CNS ORR, time on treatment, progression-free survival (PFS), CNS PFS, and overall survival.
resultsWe treated 20 patients with BrM and 21 patients with LMD. Of the patients, 41% had EGFR del19, 37% L858R, 12% ex20ins, and 10% uncommon mutations. Median lines of prior therapy were 2 (range 1-7). The ORR by a combination of Response Evaluation Criteria in Solid Tumors and Response Assessment in Neuro-Oncology brain metastases/Response Assessment in Neuro-Oncology leptomeningeal metastases was 50% (95% confidence interval [CI], 27%-73%) for patients with BrM and 33% (95% CI, 15%-57%) for patients with LMD, respectively. The median PFS was 5.8 months (95% CI, 3.6-not reached [NR]) and 7.8 months (95% CI, 4.2-12.2) for the BrM and LMD cohorts, respectively. Median overall survival was 17.4 months (15.4-NR) in the BrM cohort and 14.4 months (8.9-NR) in the LMD cohort.
conclusionsAmivantamab plus lazertinib has antitumor activity in patients with EGFR-mutant lung cancers who develop new or progressing BrM or LMD. This trial demonstrates the feasibility of including patients with LMD in prospective clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.